GLP-1 Receptor Agonist Use and Risk of Suicide Death
JAMA Internal Medicine · 01.11.2024 · 184 (11) · 1301
DOI: 10.1001/jamainternmed.2024.4369 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.11.2024. Verfasst von Peter Ueda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Suicide, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Concerns have been raised regarding a link between use of glucagon-like peptide-1 (GLP-1) receptor agonists and increased risk of suicidality and self-harm.
Objective
To assess the association between use of GLP-1 receptor agonists and the risk of suicide death in routine clinical practice. Design, Setting, and Participants This active-comparator new-user cohort study used nationwide register data from Sweden and Denmark from 2013 to 2021. Adults 18 to 84 years old who initiated treatment with GLP-1 receptor agonists or the comparator sodium-glucose cotransporter-2 (SGLT2) inhibitors were included. Data were analyzed from March to June 2024. Exposure Initiation of treatment with a GLP-1 receptor agonist or SGLT2 inhibitor. Main Outcomes and Measures The primary outcome was suicide death recorded in the cause of death registers. Secondary outcomes were the composite of suicide death and nonfatal self-harm and the composite of incident depression and anxiety-related disorders. Using propensity score weighting, hazard ratios (HRs) with 95% CIs were calculated separately in the 2 countries and pooled in a meta-analysis.
Results
In total, 124 517 adults initiated a GLP-1 receptor agonist and 174 036 initiated an SGLT2 inhibitor; among GLP-1 receptor agonist users, the mean (SD) age was 60 (13) years, and 45% were women. During a mean (SD) follow-up of 2.5 (1.7) years, 77 suicide deaths occurred among users of GLP-1 receptor agonists and 71 suicide deaths occurred among users of SGLT2 inhibitors: weighted incidences were 0.23 vs 0.18 events per 1000 person-years (HR, 1.25; 95% CI, 0.83-1.88), with an absolute difference of 0.05 (95% CI, −0.03 to 0.16) events per 1000 person-years. The HR was 0.83 (95% CI, 0.70-0.97) for suicide death and nonfatal self-harm, and the HR was 1.01 (95% CI, 0.97-1.06) for incident depression and anxiety-related disorders. Conclusions and Relevance This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of GLP-1 receptor agonists and an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. Suicide death among GLP-1 receptor agonist users was rare, and the upper limit of the confidence interval was compatible with an absolute risk increase of no more than 0.16 events per 1000 person-years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
- The Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden.
- Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
- HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Science, Norwegian University of Science and Technology, Trondheim, Norway.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Zitieren
APA
Ueda, P., Söderling, J., Wintzell, V., Svanström, H., Pazzagli, L., Eliasson, B., Melbye, M., Hviid, A., & Pasternak, B. (2024). GLP-1 Receptor Agonist Use and Risk of Suicide Death. JAMA Internal Medicine, 184(11), 1301. https://doi.org/10.1001/jamainternmed.2024.4369
Vancouver
Ueda P, Söderling J, Wintzell V, Svanström H, Pazzagli L, Eliasson B, et al. GLP-1 Receptor Agonist Use and Risk of Suicide Death. JAMA Internal Medicine. 2024;184(11):1301. doi:10.1001/jamainternmed.2024.4369
BibTeX
@article{Ueda2024,
author = {Ueda, Peter and Söderling, Jonas and Wintzell, Viktor and Svanström, Henrik and Pazzagli, Laura and Eliasson, Björn and Melbye, Mads and Hviid, Anders and Pasternak, Björn},
title = {GLP-1 Receptor Agonist Use and Risk of Suicide Death},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {11},
pages = {1301},
doi = {10.1001/jamainternmed.2024.4369}
}
EUVIMED